Raun 1998 — Ipamorelin First Selective Growth Hormone Secretagogue

European Journal of Endocrinology·November 1, 1998

K. Raun, B. S. Hansen, N. L. Johansen, H. Thøgersen, K. Madsen, M. Ankersen, P. H. Andersen

Summary

Ipamorelin showed high GH-releasing potency and selectivity, with less effect on cortisol, ACTH, and prolactin compared with older GHRPs.

Study Details

Study Design

In vitro and in vivo pharmacology study

Indication

Growth hormone secretagogue pharmacology

Intervention

Ipamorelin

Species

Animal

Risk of Bias Assessment

Foundational pharmacology; not an efficacy trial